Second Quarter 2017
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Corporate Governance
Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020. -
Dovato, INN-Dolutegravir, Lamivudine
26 April 2019 EMA/267082/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Dovato International non-proprietary name: dolutegravir / lamivudine Procedure No. EMEA/H/C/004909/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Downloaded from wizmed.com Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features ............................................................................................... -
The Academy of Medical Sciences Review 2006 Fmedsci Contents
The Academy of Medical Sciences Review 2006 FMedSci Contents 1 The Academy’s objectives and ambitions for medical science 2 A message from our President 4 Executive Director’s report 6 The strength of our Fellowship 8 How we work 10 Progress through partnership 12 Celebrating science 14 Advancing medical science and infl uencing policy 16 Building trust in science 18 Working in partnership with industry 20 The impact of research 22 Creating the next generation of medical scientists 24 Financial information 25 The Academy offi ce 14 16 18 20 22 The Academy’s objectives and ambitions for medical science The Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are converted as quickly as possible into healthcare benefi ts for society. Our 850 Fellows are the UK’s leading medical scientists from hospitals and general practice, academia, industry and the public service. Our Fellows are central to all we do. The excellence of their science, their contribution to medicine and society and the diversity of their achievements are refl ected throughout this review. The Academy seeks to play a pivotal role in determining the future of medical science in the UK, and the benefi ts that society will enjoy in years to come. We champion the UK’s strengths in medical science, including the unique opportunities for research aff orded by the NHS, encourage the implementation of new ideas and solutions – often through novel partnerships, promote careers and capacity building and help to remove barriers to progress. Throughout all our work the Academy strives to demonstrate our key attributes of excellence, independence, leadership, diversity and fl exibility. -
Dovato, INN-Dolutegravir, Lamivudine
26 April 2019 EMA/267082/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Dovato International non-proprietary name: dolutegravir / lamivudine Procedure No. EMEA/H/C/004909/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features ............................................................................................... -
Third Annual World Congress on the Insulin Resistance Syndrome Atherothrombotic Disease
Reviews/Commentaries/Position Statements PERSPECTIVES ON THE NEWS Third Annual World Congress on the Insulin Resistance Syndrome Atherothrombotic disease ZACHARY T. BLOOMGARDEN, MD thalamic “clock,” which generates protein signals feeding back to create rhythmic behaviors and metabolic changes. Rhyth- his is the second of three articles re- structure, coagulation, and platelets in a mic mRNA expression of clock genes and viewing presentations at the 3rd An- prothrombotic direction (3). adipokines can also be demonstrated in T nual World Congress on the Insulin It is not apparent why insulin resis- mouse visceral adipose tissue, with adi- Resistance Syndrome, San Francisco, Cal- tance should be linked to atherosclerosis. ponectin and resistin responses both at- ifornia, 17–19 November 2005. The thrifty genotype hypothesis suggests tenuated in obese mice. Grant showed an that there is a survival advantage to insu- animal model in which pioglitazone im- proved hepatic rhythmicity. Thus, light, Diabetes and vascular disease lin resistance during periods of feast alter- as well as other stimuli such as ambient At a symposium cosponsored by the In- nating with famine (4), but that chronic ternational Society of Diabetes and Vascu- exposure to high nutrient intake converts temperature, acts via the suprachiasmatic lar Disease (www.dvdres.com), Peter the organism to the phenotype of insulin nucleus to send signals to adipocytes, the Grant (Leeds, U.K.) discussed the role of resistance sydrome and diabetes, with en- endothelium, liver, fibroblasts, cardiac insulin signaling pathways in acute coro- ergy preferentially stored in the liver and myocytes, and multiple other tissues, reg- nary syndrome (ACS), pointing out that in fat and with the clustering of risk mark- ulating reproductive, metabolic, and be- type 2 diabetes is characterized by fasting ers we have come to identify with insulin havioral aspects of life. -
Connecting Immunology
CONNECTING IMMUNOLOGY IN THE TIME OF COVID-19 BSI VIRTUAL CONFERENCE 1-2 DECEMBER 2020 CONNECTINGLOGY NO VID-19 MU OF CO IM TIME IN THE CONNECTING CONNECTING IMMUNOLOGY IN THE TIME OF COVID-19 2 IMMUNOLOGY IN THE TIME OF COVID-19 Welcome On behalf of the BSI’s Congress Committee, I would like to welcome you all to the British Society for Immunology’s virtual conference ‘Connecting immunology in the time of COVID-19’. This is the BSI’s first ever virtual conference at this scale and our committee have worked hard to develop a diverse programme of plenary and parallel sessions covering many of the hot topics within immunology, which we hope will appeal to delegates. With our cutting-edge two-day agenda coupled with our interactive online platform, we aim to bring together immunologists from the UK and worldwide, providing attendees with the latest research developments from Gary Entrican internationally acclaimed leaders in their field. We’re honoured to welcome a number of high-profile speakers including our two keynote presenters from the US, Garry Nolan and Akiko Iwasaki. Additionally, we are privileged to be joined by Sir Patrick Vallance, the Chief Scientific Adviser to the UK Government, who will speak in our COVID-19 themed plenary session alongside Paul Moss, the lead for the UK Coronavirus Immunology Consortium. Among the many other highlights of our programme, I would particularly recommend you attend our Bright Sparks sessions on the first morning, featuring ground-breaking work from promising early career researchers. Additionally, our Coronavirus Panel Discussion on the second afternoon promises to be a fascinating exchange of views on how immunology has fed into the pandemic response. -
Product Monograph for CELSENTRI
PRODUCT MONOGRAPH PrCELSENTRI maraviroc Tablets 150 and 300 mg CCR5 antagonist ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: July 05, 2019 Submission Control No: 226222 © 2019 ViiV Healthcare group of companies or its licensor. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 60 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION..............................................................................28 OVERDOSAGE ................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ............................................................31 STORAGE AND STABILITY..........................................................................................36 -
Product Monograph for COMBIVIR
PRODUCT MONOGRAPH PrCOMBIVIR® lamivudine and zidovudine 150 mg of lamivudine and 300 mg zidovudine tablets Antiretroviral Agent ViiV Healthcare ULC 245 Boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: June 06, 2019 Submission Control No: 226229 © 2019 ViiV Healthcare ULC. All Rights Reserved. COMBIVIR is a registered trademark of the ViiV Healthcare group of companies. Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................23 -
Building Innovation, Performance and Trust
Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. -
Second Quarter 2018
Press release Second quarter 2018 Issued: Wednesday, 25 July 2018, London U.K. GSK delivers improvements in sales (at CER), margins and cash flow in Q2 2018 Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER GSK sets out new approach to Research and Development and upgrades 2018 EPS guidance F inancial highlights • Group sales: £7.3 billion, flat AER, +4% CER. Pharmaceuticals sales £4.2 billion, -3% AER, +1% CER; Vaccines £1.3 billion, +13% AER, +16% CER; Consumer Healthcare £1.8 billion, -1% AER, +3% CER • Adjusted Group operating margin: 28.8%, +0.3 percentage points AER, +0.8 percentage points CER. Pharmaceuticals: 35.3%, Vaccines 28.5%, Consumer Healthcare 19.3% • Adjusted R&D £868 million, -18% AER, -15% CER reflecting benefits of prioritisation, comparison with utilisation of Priority Review Voucher in Q2 2017 and phasing of new investments • Total EPS: 9.0p (Q2 2017: loss per share 3.7p) reflecting reduced impairments and lower charges for restructuring and changes in valuations of Consumer Healthcare and HIV businesses • Adjusted EPS growth +3% AER, +10% CER driven by operating leverage, continued financial efficiencies and reduction in minorities following completion of Consumer Healthcare buyout on 1 June 2018 • H1 2018 free cash flow £0.8 billion (H1 2017: £0.4 billion) • 19p dividend declared for quarter. Continue to expect 80p for FY 2018 • New major restructuring programme expected to deliver annual cost savings of £400 million by 2021. Charges expected to be £0.8 billion cash and £0.9 billion non-cash over next 3 years • Now expect 2018 Adjusted EPS growth of 7 to 10% at CER if no substitutable generic competitor to Advair introduced in US in 2018. -
Newsletter Spring 2018 This Is Engineering Campaign Goes Live
This is Engineering campaign goes live n January, the Academy launched This is Engineering, an engineering, which are often that it is narrow, technical unparalleled multi-year perception-change campaign that and traditional. Iseeks to rebrand engineering for young people and their influencers to encourage them to take up careers in engineering. It centres on an online and social media advertising campaign, complemented by a programme of PR activity that highlights The UK’s impending departure from the European Union and the critical role that engineering plays in shaping the future. the development of a new industrial strategy present both The first five adverts focus on engineers working in sport, an imperative and a unique opportunity to refocus efforts on design, space, fashion and technology. They direct audiences to boosting the supply of UK homegrown talent. Existing STEM an online hub, where they can learn more about the engineers engagement initiatives over the past 10 years have not had and access practical information about how to pursue a career the impact expected. The Academy has set out to lead the in engineering. profession in taking a different approach, and will work with partners from across engineering to promote the profession as In the first seven weeks following launch, the campaign reached attractive and accessible to young people. a potential 31 million people, seven million of whom have watched the videos. It also gained coverage in The Times, on Sky This is Engineering launched on 24 January, and targets 13 News, BBC Radio 4 and Radio 5 Live, among other media titles. -
E2017137 (PDF)
History of Modern Biomedicine Research Group School of History, Queen Mary University of London Mile End Road, London E1 4NS website: www.histmodbiomed.org AUDIO INTERVIEW TRANSCRIPT Sanger, Gareth: transcript of an audio interview (08-Dec-2016) Interviewer: Tilli Tansey Transcriber: Debra Gee Editors: Tilli Tansey, Apostolos Zarros Date of publication: 05-May-2017 Date and place of interview: 08-Dec-2016; Queen Mary University of London Publisher: Queen Mary University of London Collection: History of Modern Biomedicine Interviews (Digital Collection) Reference: e2017137 Number of pages: 25 DOI: 10.17636/01022653 Acknowledgments: The project management of Mr Adam Wilkinson and the technical support of Mr Alan Yabsley are gratefully acknowledged. The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey). Citation: Tansey E M (intvr); Tansey E M, Zarros A (eds) (2017) Sanger, Gareth: transcript of an audio interview (08- Dec-2016). History of Modern Biomedicine Interviews (Digital Collection), item e2017137. London: Queen Mary University of London. Note: Audio interviews are conducted following standard oral history methodology, and have received ethical approval (reference QMREC 0642). Related material has been deposited in the Wellcome Library. © The Trustee of the Wellcome Trust, London, 2017 History of Modern Biomedicine Interviews (Digital Collection) - Sanger, G e2017137 | 2 Sanger, Gareth: transcript of an audio interview (08-Dec-2016)* Biography: Professor Gareth Sanger BSc PhD DSc FBPhS FRSB (b.